Tislelizumab: all 398 studies that test it
Page 1 of 4. Open to participants first (214), then studies with results posted, then the rest; newest registration first within each.
- Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung CancerNot yet recruitingNCT07845916Phase 2
- A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCRecruitingNCT07815223Phase 2
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
- Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCCNot yet recruitingNCT07776340Phase 2
- Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II TrialNot yet recruitingNCT07775040Phase 2
- A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCRecruitingNCT07733180Phase 2
- Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingNCT07686926Phase 2
- Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System DiseaseNot yet recruitingNCT07681297Phase 1/2
- A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic CancerRecruitingNCT07671339Phase 1
- Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.Not yet recruitingNCT07655661Phase 2
- Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ AdenocarcinomaRecruitingNCT07569068Phase 2
- Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLCNot yet recruitingNCT07561983Phase 2
- Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab ImmunotherapyRecruitingNCT07561060Phase 1/2
- Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and DiabetesNot yet recruitingNCT07557914Phase 2
- A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot yet recruitingNCT07535840Not applicable
- Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2Not yet recruitingNCT07531979Phase 2
- Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy FailureRecruitingNCT07528274Phase 2
- Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow MarginNot yet recruitingNCT07518706Phase 2
- Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell LymphomaRecruitingNCT07502768Phase 1/2
- A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung CancerNot yet recruitingNCT07485920Phase 4
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of RecurrenceRecruitingNCT07475026Phase 3
- LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal CancerNot yet recruitingNCT07453875Phase 1
- Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLCNot yet recruitingNCT07432984Phase 2
- Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular LymphomaRecruitingNCT07418190Phase 2
- Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaRecruitingNCT07413354Phase 2
- Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid TumorsNot yet recruitingNCT07396090Not applicable
- Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07388758Phase 2
- Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic AdenocarcinomaRecruitingNCT07377045Phase 1
- Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal CarcinomaNot yet recruitingNCT07373990Phase 3
- Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory CanalRecruitingNCT07370337Phase 2
- Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UCEnrolling by invitationNCT07353294Phase 1
- Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue CancerNot yet recruitingNCT07346807Phase 2
- Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma PeritoneiRecruitingNCT07341360Early Phase 1
- TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant ChemoimmunotherapyRecruitingNCT07330037Phase 2
- Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)RecruitingNCT07320105Phase 4
- Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)RecruitingNCT07317609Phase 1
- A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07315750Phase 3
- A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10Not yet recruitingNCT07304258Phase 2
- T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to ImmunotherapyNot yet recruitingNCT07300891Phase 2
- Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBCRecruitingNCT07296705Phase 2
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRCRecruitingNCT07244705Phase 1/2
- Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular CarcinomaRecruitingNCT07243691Not applicable
- Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerRecruitingNCT07233252Phase 2
- Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon CancerNot yet recruitingNCT07132008Phase 3
- SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLCRecruitingNCT07131319Phase 2/3
- Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUCRecruitingNCT07126119Phase 2
- Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLCRecruitingNCT07120282Phase 2
- Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer PatientsRecruitingNCT07119996Phase 1
- Perioperative Immunotherapy for Resectable Limited-Stage SCLCRecruitingNCT07109401Phase 2
- Study of ZG005 in Combination With Platinum-Based Chemotherapy in Participants With Advanced Biliary Tract CarcinomaRecruitingNCT07099547Phase 2
- Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07086456Phase 2
- Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line TreatmentNot yet recruitingNCT07078305Phase 2
- WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical TherapyNot yet recruitingNCT07077369Phase 1
- Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ CancerNot yet recruitingNCT07068516Phase 3
- A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT07062484Not applicable
- A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaRecruitingNCT07059299Phase 1
- Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLCRecruitingNCT07050056Phase 2
- Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and BevacizumabRecruitingNCT07047586Phase 2
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07043400Phase 3
- Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07039162Phase 2
- A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FLNot yet recruitingNCT07031700Phase 2
- Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar CholangiocarcinomaRecruitingNCT07030140Phase 2
- Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal CancerNot yet recruitingNCT07025850Phase 1/2
- Tislelizumab Combined With Chemotherapy for the Perioperative Treatment of Esophageal Squamous CarcinomaNot yet recruitingNCT07019181Phase 2
- A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLCRecruitingNCT06969612Phase 1
- The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ ECNot yet recruitingNCT06965829Phase 2
- Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line InductionNot yet recruitingNCT06951841Phase 4
- A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT06944496Phase 3
- Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.RecruitingNCT06940388Phase 2
- Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder CancerRecruitingNCT06916494Phase 1
- Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06914011Phase 3
- Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk CholangiocarcinomaNot yet recruitingNCT06903273Phase 2
- An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung CancerNot yet recruitingNCT06883552Phase 2
- Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric CancerNot yet recruitingNCT06871527Phase 1/2
- Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)RecruitingNCT06860477Phase 2
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver MetastasesRecruitingNCT06856837Phase 2
- IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)RecruitingNCT06849986Phase 2
- LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver MetastasisRecruitingNCT06848465Phase 1
- Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaRecruitingNCT06838910Phase 2
- Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLCRecruitingNCT06838208Phase 2
- Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingNCT06825494Phase 1/2
- Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC CachexiaNot yet recruitingNCT06793228Phase 2
- Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06764355Phase 2
- BV in the Treatment of Relapsed/refractory Hodgkin LymphomaNot yet recruitingNCT06761911Phase 4
- An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line SettingRecruitingNCT06749886Phase 2
- Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expressionRecruitingNCT06749860Phase 2
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint InRecruitingNCT06745908Phase 3
- Preoperative Tislelizumab -Cetuximab - Chemotherapy Followed by Salvage Surgery and Adjuvant Tislelizumab -Cetuximab for Resectable, Locally Recurrent Oral and Oropharyngeal Squamous Cell CarcinomaNot yet recruitingNCT06728618Phase 2
- Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCCRecruitingNCT06725498Phase 2
- Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor EntitiesRecruitingNCT06722183Phase 2
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- Tislelizumab as Single-Agent Neoadjuvant Immunotherapy in Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06692270Phase 2
- Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung CancerRecruitingNCT06659042Phase 2
- Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）RecruitingNCT06647680Phase 2
- Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06646588Phase 2
- EVM16 Injection as a Single and Combination With Tislelizumab in Solid TumorsRecruitingNCT06541639Phase 1
- Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical StudyRecruitingNCT06538896Phase 2
- Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLCRecruitingNCT06536868Phase 2
- Tislelizumab in People With Colorectal CancerRecruitingNCT06529523Phase 2
- Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal CancerRecruitingNCT06520683Phase 3